Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy-Reference-Cited by-同舟云学术

Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy

Published:2017-12 Issue:1 Volume:15 Page:
ISSN:1479-5876
Container-title:Journal of Translational Medicine
language:en
Short-container-title:J Transl Med

Author:

Yu Huan,Ma Meng,Yan Junya,Xu Longwen,Yu Jiayi,Dai Jie,Xu Tianxiao,Tang Huan,Wu Xiaowen,Li Siming,Lian Bin,Mao Lili,Chi Zhihong,Cui Chuanliang,Guo Jun,Kong Yan

Funder

the Major State Basic Research Development Program of China

National Natural Science Foundation of China

Beijing Municipal Natural Science Foundation

Beijing Baiqianwan Talents Project

Beijing Municipal Administration of Hospitals Clinical medicine Development of special funding support

Beijing Municipal Science & Technology Commission

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12967-017-1344-z.pdf

Reference36 articles.

1. Kong Y, Si L, Zhu Y, et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res. 2011;17(7):1684–91.

2. Zingg D, Debbache J, Schaefer SM, et al. The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nat Commun. 2015;6:6051.

3. Si L, Kong Y, Xu X, et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer. 2012;48(1):94–100.

4. Young K, Minchom A, Larkin J. BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation. Future Oncol. 2012;8(5):499–507.

5. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707–14.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Repurposing of the Cardiovascular Drug Statin for the Treatment of Cancers: Efficacy of Statin–Dipyridamole Combination Treatment in Melanoma Cell Lines;Biomedicines;2024-03-21

2. New Approaches to Targeted Therapy in Melanoma;Cancers;2023-06-17

3. lncRNAs-EZH2 interaction as promising therapeutic target in cutaneous melanoma;Frontiers in Molecular Biosciences;2023-05-31

4. Establishment of a BRAF V595E‐mutant canine prostate cancer cell line and the antitumor effects of MEK inhibitors against canine prostate cancer;Veterinary and Comparative Oncology;2023-02-20

5. Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma;International Journal of Molecular Sciences;2023-01-19